The oncogenic role of exosomal miR‐20a in promoting NSCLC progression and chemoresistance through PTEN suppression and PI3K/AKT activation highlights the therapeutic potential of targeting this pathway. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.